Aligos presents EASL data on pevifoscorvir sodium Phase 2 HBV dose selection

Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc.

ALGS

0.00
  • Aligos Therapeutics outlined upcoming clinical and preclinical data disclosures at EASL Congress 2026 in Barcelona, with posters scheduled for May 27-30.
  • Key clinical readouts will cover pevifoscorvir sodium monotherapy in chronic hepatitis B, highlighting sustained reductions in viral antigens during follow-up and broad antiviral activity across patient subgroups.
  • Additional presentations will address dose-selection support work for pevifoscorvir sodium, aiming to inform next-stage development decisions.
  • Pipeline updates will also include preclinical combination activity for an HBV antisense oligonucleotide program, along with earlier research in hepatitis delta and an oral PD-1/PD-L1 inhibitor concept for HBV and liver cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130205PRIMZONEFULLFEED9717752) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.